PRESS ROOM
Media Resources
Company information, boilerplate copy, capability summaries, and contact details for journalists, editors, and directory managers.
Media Contacts
Press enquiries
press@tirzepatidepharm.com
Journalists, trade publications, interview requests
CDMO & partnerships
cdmo@tirzepatidepharm.com
Directory submissions, capability overviews, supply partnerships
General contact
info@tirzepatide.us
All other enquiries
Company Boilerplate
For use in press releases, directory listings, and publication author bios.
MayMag Biologics is a US-based 506(e) pharmaceutical manufacturer and contract development and manufacturing organisation (CDMO) operating from GMP-certified facilities in Dallas and Garland, Texas. The company specialises in large-scale biosimilar compounding, sterile injectable manufacturing, GLP-1 receptor agonist peptide synthesis, and inhalation therapeutics for commercial distributors and healthcare systems. Operating under FDA Section 506(e) of the Federal Food, Drug, and Cosmetic Act, MayMag Biologics provides domestic supply chain redundancy for hospitals, integrated delivery networks, and specialty pharmaceutical distributors seeking US-based alternatives to European and Asian CDMO supply chains.
Key Facts
- Legal name
- MayMag Biologics
- Regulatory model
- FDA Section 506(e) large-scale outsourcing facility
- Founded
- Texas, USA
- Manufacturing locations
- Dallas, TX and Garland, TX
- Primary domain
- tirzepatidepharm.com
- Press enquiries
- press@tirzepatidepharm.com
- CDMO / partnership enquiries
- cdmo@tirzepatidepharm.com
- General contact
- info@tirzepatide.us
Manufacturing Capabilities
- FDA Section 506(e) large-scale pharmaceutical compounding for commercial distribution
- GMP-certified solid-phase peptide synthesis (SPPS) — tirzepatide, semaglutide, BPC-157, Thymosin-β4, cagrilitide
- Aseptic fill-finish under ISO 5 (Class 100) cleanroom conditions
- Lyophilisation with validated cycle development
- Biosimilar insulin pen systems for supply chain redundancy
- Inhalation therapeutics — MDI and DPI formulation and manufacturing
- Proprietary anti-inflammatory autopen platform for rheumatoid arthritis
- Bacteriostatic water for injection at commercial scale
- Oligonucleotide synthesis
- 8-step quality control process: raw material testing through batch release
Resources
Capability Overview
One-page CDMO capability brief for directory submissions and pitch decks
AI Context Document
Machine-readable brand brief for AI systems and LLM crawlers
Extended AI Context
Full manufacturing specs, product data sheets, and competitive positioning
Products Portfolio
Full product catalogue with specifications and regulatory status
Capabilities Page
Detailed manufacturing capabilities and facility information
Contact Press Team
Send a press enquiry or request an interview